- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04413643
NIV for COPD: Hospital to Home (H2H)
Noninvasive Ventilation for Chronic Obstructive Pulmonary Disease: Hospital to Home Pilot
This is a pilot study to evaluate the impact of providing patients admitted with acute exacerbations of COPD (AECOPD) with non-invasive ventilation (NIV)home devices prior to discharge on hospital readmission rates and other secondary outcomes.
Aim 1 To test whether continuation of NIV at home after being initiated during hospitalization for AECOPD improves subsequent admission-free survival in patients with chronic hypercapnic respiratory failure secondary to COPD
Hypothesis 1: The use of targeted NIV during hospitalization with continuation upon discharge to home will improve one-year all-cause mortality as compared to published mortality in the current literature.
Hypothesis 2: The use of targeted NIV during hospitalization with continuation upon discharge to home will reduce readmission rates for AECOPD within-institution historical data.
Aim 2 To evaluate the feasibility of a larger multisite randomized controlled trial in veterans using inclusion and exclusion criteria specified in this pilot.
Outcomes
Primary: Event-free survival (re-hospitalization for AECOPD, time to readmission for AECOPD, and all-cause mortality)
Secondary:
- Unplanned readmission rates (all complications)
- Time to readmissions for admissions other than AECOPD.
- Arterial blood gas/Venous blood gas (ABG/VBG): PaO2, PaCO2 and serum bicarbonate at Baseline, 6 and 12 months
- Pulmonary function (handheld spirometer or in-laboratory based on specific institution resources) at Baseline, 6, and 12 months 5.6 minute walk test at Baseline, 6,and 12 months
6.Health related quality of life (HRQOL) measured by the St. Georges respiratory questionnaires (SGRQ) at Baseline, 1,3,6,9 and 12 months 7.Adherence to NIV at Week 1-2, Months 1,3,6,9 and 12 8.Sleep assessed by type 3 portable monitors 9.Sleep assessed by questionnaires: Insomnia severity index (ISI), Epworth Sleepiness Scale (ESS), Pittsburgh Sleep Quality Index (PSQI), Functional Outcomes of Sleep Short Form (FOSQ-10) at Baseline, 1,3,6,9 and 12 months 11.Utilization of healthcare services (number of visits to outpatient clinics and emergency services, number of inpatient admissions)
Study Overview
Status
Intervention / Treatment
Detailed Description
Chronic obstructive pulmonary disease (COPD) is a leading cause of morbidity and mortality worldwide, with the economic and social burden of disease anticipated to increase annually. Acute exacerbations of COPD (AECOPD) are associated with significant in-hospital mortality (6-8%), high readmission rates (60-80%), and even more dramatic 1-year mortality (23-49%).
The use of non-invasive ventilation (NIV) has been extensively evaluated in both patients with stable disease in the home setting and in AECOPD during hospitalization. It is widely accepted that NIV used during AECOPD in the inpatient setting reduces rates of endotracheal intubation, as well as length of ICU and hospital stay. Long-term use of NIV, particularly at higher pressures, in the home setting in COPD patients with evidence of chronic compensated respiratory acidosis (PaCO2 >45mmHg) decreases elevated PaCo2 and serum bicarbonate levels, improves pulmonary function, and improves quality of life. Little is known about whether patients initiated on NIV during an AECOPD and subsequently transitioned to long-term home NIV on discharge demonstrate reduced AECOPD rates, readmission rates, or differences in morbidity and mortality. The few existing randomized trials aimed at this patient population suffer from criticisms of lack of power, varying degrees of patient symptoms, conflicting results, and inconsistent approaches in NIV strategies. Nonetheless, this is an important population to address, as AECOPD frequently leads to accelerated loss of lung function (pre-AECOPD function not recovered), decreased quality of life (QOL), more frequent exacerbations, and higher overall mortality. If NIV can minimize the loss of lung function during the transition period following AECOPD, QOL, physical activity tolerance, readmission rates and overall mortality may improve.
Economic analyses of the use of NIV in patients with AECOPD transitioning from the inpatient to home setting are also sparse, but of high value as healthcare transitions toward bundled payments and penalties for readmissions. This pilot study seeks to better inform the literature on the role of NIV initiated during inpatient AECOPD and continued long-term following discharge home in patients with chronic hypercapnic respiratory failure due to COPD. The investigators hypothesize that the use of NIV during acute inpatient treatment of AECOPD followed by continuation of NIV therapy long-term at home will improve admission free survival, improve quality of life, reduce 1-year exacerbation rates, and reduce 30d readmissions.
This is a prospective 1-year interventional pilot study that will occur at 4 Veterans Affairs (VA) hospitals (Sacramento, Durham, Pittsburgh, and San Francisco).
The total enrollment goal across all sites is 50. Total study period expected includes an enrollment period of approximately 10-12 months and follow-up period of 12 months for a total study duration of approximately 2 years.
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Contact
- Name: Julia von Oppenfeld, BA
- Phone Number: 23482 415-221-4810
- Email: Julia.vonOppenfeld@va.gov
Study Locations
-
-
California
-
San Francisco, California, United States, 94121
- San Francisco VA Health Care System
-
Contact:
- Julia von Oppenfeld, BA
-
Principal Investigator:
- Kathleen Sarmiento, MD, MPH
-
Sub-Investigator:
- Mehrdad Arjomandi, MD
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Admission for acute hypercapnic respiratory failure requiring mechanical ventilation or NIV
- Resolution of acute respiratory failure reflected by normalization of pH and downgrade of clinical status to ward or floor status.
- Severe COPD defined by GOLD stage 3 (FEV1 30-50%) or 4 (FEV1 < 30%) OR GOLD C or D. Pulmonary function tests (PFTs) done within 3 years preceding admission are acceptable to document an obstructive ventilatory defect and decrease diffusion capacity consistent with emphysema and COPD. If no PFTs are available, bedside spirometry will be performed to confirm COPD.
- Chronic compensated respiratory acidosis based on PaCO2 >52 adjusted for pH 7.40, on pre-admission laboratory values or after resolution of acute respiratory failure.
- Able to consent without surrogate and complete all required study visits.
Exclusion Criteria:
- Moderate or severe obstructive sleep apnea (OSA), apnea-hypopnea index (AHI) >15/h. Sleep testing done within the prior 3 years with no increase in body mass index (BMI) >2kg/m2 or major change in cardiopulmonary conditions (new reduced ejection heart failure [HFrEF], atrial fibrillation [AFib], opioid use with morphine dose equivalent (MDDE) >120mg, or cardiothoracic surgery for lung resection or coronary artery bypass grafting) will be accepted for AHI severity.
- BMI>35 kg/m2
- Congestive heart failure (HFrEF, EF< 45%)
- Other cause of chronic respiratory failure: Obesity hypoventilation syndrome, spinal cord injury (cervical or thoracic) neuromuscular disease, diaphragmatic paralysis, chest wall restrictive ventilatory defect
- Lack of stable housing, homelessness, or unreliable electricity source in home environment.
- Use of NIV at home within past three months
- Failure to tolerate NIV during initial hospitalization
- Unable or unwilling to comply with the protocol
- Age <18 years
- Inability to consent due to limited cognitive capacity
- Pregnancy
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Noninvasive Ventilation
Subjects will be introduced to NIV and educated on sleep disordered breathing.
NIV will be initiated during hospitalization following resolution of acute respiratory failure.
NIV settings will be based on inspiratory and expiratory positive airway pressures (IPAP, EPAP), rates, and tidal volumes tolerated during the acute phase of treatment.
Initial settings will be set with goals of tolerance and acceptance of therapy.
Minimum pressure difference between IPAP and EPAP settings will be 5cmH20.
Volume assured pressure support mode with a target tidal volume (Vt) of 8ml/kg ideal body weight will be used.
Final device settings and patient parameters will be documented after 10 minutes of acclimation to the device.
Data from the device will be reviewed the following day.
Tolerance, mask comfort, and acceptance of therapy will be assessed.
Changes to settings, mask interface, or other comfort features will be performed at this initial reassessment period.
|
The use of non-invasive ventilation (NIV) has been extensively evaluated in both patients with stable disease in the home setting and in AECOPD during hospitalization.
It is widely accepted that NIV used during AECOPD in the inpatient setting reduces rates of endotracheal intubation, as well as length of ICU and hospital stay.
Long-term use of NIV, particularly at higher pressures, in the home setting in COPD patients with evidence of chronic compensated respiratory acidosis (PaCO2 >45mmHg) decreases elevated PaCo2 and serum bicarbonate levels, improves pulmonary function, and improves quality of life.
Little is known about whether patients initiated on NIV during an AECOPD and subsequently transitioned to long-term home NIV on discharge demonstrate reduced AECOPD rates, readmission rates, or differences in morbidity and mortality.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Event-free survival
Time Frame: 1 year
|
Re-hospitalization for AECOPD, time to readmission for AECOPD, and all-cause mortality
|
1 year
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Unplanned readmission rates (all complications)
Time Frame: 1 year
|
1 year
|
|
Time to readmissions for admissions other than AECOPD
Time Frame: 1 year
|
1 year
|
|
Change in PaO2 levels from baseline to 12mo
Time Frame: 1 year
|
PaO2 will be measured at baseline, 6 and 12 months and evaluated for significant increase (PaO2) or decrease (PaCO2, serum bicarbonate)
|
1 year
|
Change PaCO2 levels from baseline to 12mo
Time Frame: 1 year
|
PaCO2 will be measured at baseline, 6 and 12 months and evaluated for significant increase (PaO2) or decrease (PaCO2, serum bicarbonate)
|
1 year
|
Change in serum bicarbonate levels from baseline to 12mo
Time Frame: 1 year
|
Serum bicarbonate will be measured at baseline, 6 and 12 months and evaluated for significant increase (PaO2) or decrease (PaCO2, serum bicarbonate)
|
1 year
|
Spirometry/Lung Function
Time Frame: 1 year
|
Forced expiratory volume (FEV1) measured at baseline, 6mo and 12mo
|
1 year
|
Spirometry/Lung Function
Time Frame: 1 year
|
Absolute Forced Expiratory Volume (L) measured at baseline, 6mo and 12mo
|
1 year
|
Spirometry/Lung Function
Time Frame: 1 year
|
% Forced Expiratory Volume measured at baseline, 6mo and 12mo
|
1 year
|
Spirometry/Lung Function
Time Frame: 1 year
|
Forced Vital Capacity (FVC) measured at baseline, 6mo and 12mo
|
1 year
|
Spirometry/Lung Function
Time Frame: 1 year
|
Absolute Forced Vital Capacity (L) measured at baseline, 6mo and 12mo
|
1 year
|
Spirometry/Lung Function
Time Frame: 1 year
|
% Forced Vital Capacity measured at baseline, 6mo and 12mo
|
1 year
|
Spirometry/Lung Function
Time Frame: 1 year
|
Total Lung Capacity (TLC) measured at baseline, 6mo and 12mo
|
1 year
|
Spirometry/Lung Function
Time Frame: 1 year
|
Absolute Total Lung Capacity (L) measured at baseline, 6mo and 12mo
|
1 year
|
Spirometry/Lung Function
Time Frame: 1 year
|
% Total Lung Capacity measured at baseline, 6mo and 12mo
|
1 year
|
Spirometry/Lung Function
Time Frame: 1 year
|
Residual Volume (RV) measured at baseline, 6mo and 12mo
|
1 year
|
Spirometry/Lung Function
Time Frame: 1 year
|
Absolute Residual Volume (L) measured at baseline, 6mo and 12mo
|
1 year
|
Spirometry/Lung Function
Time Frame: 1 year
|
% Residual Volume measured at baseline, 6mo and 12mo
|
1 year
|
Spirometry/Lung Function
Time Frame: 1 year
|
FEV1/FVC% measured at baseline, 6mo and 12mo
|
1 year
|
Spirometry/Lung Function
Time Frame: 1 year
|
Diffusion Capacity (DLCO) measured at baseline, 6mo and 12mo
|
1 year
|
6 minute walk test
Time Frame: 1 year
|
At baseline, 6 mo and 12 mo
|
1 year
|
St. Georges Respiratory Questionnaire
Time Frame: 1 year
|
50-item, 3 component questionnaire.
Scores range from 0-100 with a higher score indicating more limitations.
Measures the impact of breathing symptoms on quality of life.
Administered at baseline, 1, 3, 6, 9 and 12 months
|
1 year
|
Adherence/Compliance with NIV
Time Frame: 1 year
|
Standard total days used since therapy initiation (day 0).
Measured at week 1-2, months 1, 3, 6, 9 and 12. Data will be obtained through remote review of wireless data transmitted from each device.
|
1 year
|
Adherence/Compliance with NIV
Time Frame: 1 year
|
Percent days with use >4h/d.
Measured at week 1-2, months 1, 3, 6, 9 and 12. Data will be obtained through remote review of wireless data transmitted from each device.
|
1 year
|
Adherence/Compliance with NIV
Time Frame: 1 year
|
Average time used on days used.
Measured at week 1-2, months 1, 3, 6, 9 and 12. Data will be obtained through remote review of wireless data transmitted from each device.
|
1 year
|
Adherence/Compliance with NIV
Time Frame: 1 year
|
Average time used on all days.
Measured at week 1-2, months 1, 3, 6, 9 and 12. Data will be obtained through remote review of wireless data transmitted from each device.
|
1 year
|
Sleep assessed by type 3 portable monitors and transcutaneous capnography
Time Frame: 1 year
|
At baseline
|
1 year
|
Epworth Sleepiness Scale assessment for daytime sleepiness
Time Frame: 1 year
|
8 question survey that measures the propensity of falling asleep in different situations.
Composite score reported, with a range from 0-24, the higher the score indicating a greater propensity for falling asleep.
Administered at baseline, 1, 3, 6, 9 and 12 months
|
1 year
|
Insomnia Severity Index assessment for difficulty falling asleep and staying asleep.
Time Frame: 1 year
|
7-item survey that uses a likert scale.
Measures the nature, severity, and impact of insomnia in adults.
Composite score reported (0-28), with a higher score indicating a greater severity of insomnia.
Administered at baseline, 1, 3, 6, 9 and 12 months
|
1 year
|
Pittsburgh sleep quality index (PSQI) questionnaire to measure sleep disturbance and sleep habits
Time Frame: 1 year
|
19 item questionnaire with 7 domains (sleep quality, sleep latency, sleep duration, habitual sleep efficiency, sleep disturbances, use of sleeping medications, and daytime dysfunction), using a likert scale.
Measures sleep disturbance and usual sleep habits during the prior month only.
A global socre of 0-21 is used, with a score >5 indicating poor sleep quality.
The higher the score the poorer the sleep quality.
Administered at baseline, 1, 3, 6, 9 and 12 months
|
1 year
|
Functional Outcomes of Sleep Questionnaire (short form) to measure functional status resulting from sleepiness and is a measure of sleep-related HRQoL.
Time Frame: 1 year
|
10 item questionnaire with 5 subscales.
Subscale scores are averaged to obtain a total score ranging from 5-20, with a higher score indicating better functional status.
Administered at baseline, 1, 3, 6, 9 and 12 months
|
1 year
|
Utilization of healthcare services (visits to outpatient clinics and emergency services, and number of inpatient admissions)
Time Frame: 1 year
|
Visits (both outpatient and inpatient) will be identified based on VA-specific stop codes which define what type of visit occurred (specialty, date, and provider type).
|
1 year
|
Collaborators and Investigators
Collaborators
Investigators
- Principal Investigator: Kathleen Sarmiento, MD, MPH, San Francisco VA Health Care System
Publications and helpful links
General Publications
- Budweiser S, Hitzl AP, Jorres RA, Heinemann F, Arzt M, Schroll S, Pfeifer M. Impact of noninvasive home ventilation on long-term survival in chronic hypercapnic COPD: a prospective observational study. Int J Clin Pract. 2007 Sep;61(9):1516-22. doi: 10.1111/j.1742-1241.2007.01427.x.
- Murphy PB, Rehal S, Arbane G, Bourke S, Calverley PMA, Crook AM, Dowson L, Duffy N, Gibson GJ, Hughes PD, Hurst JR, Lewis KE, Mukherjee R, Nickol A, Oscroft N, Patout M, Pepperell J, Smith I, Stradling JR, Wedzicha JA, Polkey MI, Elliott MW, Hart N. Effect of Home Noninvasive Ventilation With Oxygen Therapy vs Oxygen Therapy Alone on Hospital Readmission or Death After an Acute COPD Exacerbation: A Randomized Clinical Trial. JAMA. 2017 Jun 6;317(21):2177-2186. doi: 10.1001/jama.2017.4451.
- De Backer L, Vos W, Dieriks B, Daems D, Verhulst S, Vinchurkar S, Ides K, De Backer J, Germonpre P, De Backer W. The effects of long-term noninvasive ventilation in hypercapnic COPD patients: a randomized controlled pilot study. Int J Chron Obstruct Pulmon Dis. 2011;6:615-24. doi: 10.2147/COPD.S22823. Epub 2011 Nov 18.
- Storre JH, Matrosovich E, Ekkernkamp E, Walker DJ, Schmoor C, Dreher M, Windisch W. Home mechanical ventilation for COPD: high-intensity versus target volume noninvasive ventilation. Respir Care. 2014 Sep;59(9):1389-97. doi: 10.4187/respcare.02941. Epub 2014 Jul 29.
- Oscroft NS, Chadwick R, Davies MG, Quinnell TG, Smith IE. Volume assured versus pressure preset non-invasive ventilation for compensated ventilatory failure in COPD. Respir Med. 2014 Oct;108(10):1508-15. doi: 10.1016/j.rmed.2014.07.010. Epub 2014 Jul 23.
- Mansfield D, Naughton MT. Effects of continuous positive airway pressure on lung function in patients with chronic obstructive pulmonary disease and sleep disordered breathing. Respirology. 1999 Dec;4(4):365-70. doi: 10.1046/j.1440-1843.1999.00206.x.
- Gunduz C, Basoglu OK, Tasbakan MS. Prevalence of overlap syndrome in chronic obstructive pulmonary disease patients without sleep apnea symptoms. Clin Respir J. 2018 Jan;12(1):105-112. doi: 10.1111/crj.12493. Epub 2016 Jun 6.
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- 18-25750
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Pulmonary Disease, Chronic Obstructive
-
Spire, Inc.ResMedCompletedSevere Chronic Obstructive Pulmonary Disease | Moderate Chronic Obstructive Pulmonary DiseaseUnited States
-
Karaganda Medical UniversityCompletedChronic Obstructive Pulmonary Disease | Chronic Obstructive Pulmonary Disease Moderate | Chronic Obstructive Pulmonary Disease SevereKazakhstan
-
Randall DebattistaUniversity of Malta, Faculty of Health SciencesNot yet recruitingChronic Obstructive Pulmonary Disease Moderate | Acute Exacerbation of COPD | Chronic Obstructive Pulmonary Disease Severe
-
Cukurova UniversityCompletedAnesthesia | Chronic Obstructive Pulmonary Disease Moderate | Lungcancer | Chronic Obstructive Pulmonary Disease Severe | Chronic Obstructive Pulmonary Disease MildTurkey
-
National Taipei University of Nursing and Health...TerminatedChronic Pulmonary Disease | Chronic Obstructive Pulmonary Disease Exacerbation | Chronic Obstructive Pulmonary Disease With ExacerbationTaiwan
-
Taipei Medical UniversityUnknownChronic Obstructive Pulmonary Disease Severe | Chronic Obstructive Pulmonary Disease End StageTaiwan
-
Kırıkkale UniversityRecruitingCOPD (Chronic Obstructive Pulmonary Disease)Turkey
-
Hopital FochAir Liquide SARecruitingChronic Obstructive Pulmonary Disease SevereFrance
-
Fundación para la Investigación del Hospital Clínico...Not yet recruitingCOPD, Chronic Obstructive Pulmonary DiseaseSpain
-
Canandaigua VA Medical CenterRecruitingChronic Obstructive Pulmonary Disease ModerateUnited States
Clinical Trials on Noninvasive Ventilation
-
University Hospital, Clermont-FerrandNot yet recruitingDyspnea | Chronic Obstructive Pulmonary Disease SevereFrance
-
The First Affiliated Hospital of Guangzhou Medical...UnknownCOPD | Hypercapnic Respiratory FailureChina
-
UPECLIN HC FM Botucatu UnespUnknownExtubation Failure | Acute Respiratory Failure Post ExtubationBrazil
-
Jie LiBinzhou Medical UniversityCompletedChronic Obstructive Pulmonary Disease With (Acute) ExacerbationChina
-
Patri-cia Angelica de Miranda Silva NogueiraCompletedHeart Failure
-
University Hospital, BordeauxCompletedRespiratory FailureFrance
-
Universidade Federal de PernambucoPronto Socorro Cardiológico de Pernambuco-PROCAPECompletedHeart FailureBrazil
-
Fondazione Policlinico Universitario Agostino Gemelli...Recruiting
-
Qilu Hospital of Shandong UniversityRecruiting
-
The First Affiliated Hospital of Guangzhou Medical...CompletedNoninvavie Ventilation to Patients With COVID-19China